Viyash Scientific Ltd Downgraded to Hold Amid Mixed Financial and Technical Signals

Quality Grade Improvement but Underlying Concerns Persist

One of the key drivers behind the rating change was the upgrade in Viyash Scientific’s quality grade from below average to average. The company demonstrated robust sales growth of 20.85% and EBIT growth of 28.24% over the past five years, signalling healthy operational expansion. Additionally, the average EBIT to interest coverage ratio stands at a respectable 2.30, indicating an improved ability to service interest expenses compared to previous periods.

However, certain financial metrics temper this optimism. The average debt to EBITDA ratio remains elevated at 9.68, suggesting a relatively high leverage position that could constrain financial flexibility. Net debt to equity is moderate at 0.46, but the return on capital employed (ROCE) and return on equity (ROE) averages are modest at 6.09% and 4.59% respectively, reflecting limited profitability relative to capital and shareholder funds. Institutional holding has also declined to 8.26%, indicating waning confidence from sophisticated investors.

When benchmarked against peers, Viyash’s quality rating is average, trailing behind companies like Gland Pharma and Emcure Pharma, which maintain good quality grades. This suggests that while the company has made strides, it still lags behind sector leaders in operational efficiency and financial robustness.

Valuation Moves from Expensive to Fair, Enhancing Investment Appeal

Viyash Scientific’s valuation grade has improved from expensive to fair, a significant factor influencing the downgrade to Hold. The company currently trades at a price-to-earnings (PE) ratio of 46.69, which, while still elevated, is more reasonable relative to its peer group where companies like Wockhardt and Sai Life Sciences command PE ratios exceeding 70. The price-to-book value stands at 3.85, reflecting a moderate premium over book value.

Enterprise value multiples also support this fair valuation stance, with EV to EBIT at 24.22 and EV to EBITDA at 16.05. The PEG ratio of 1.10 indicates that the stock’s price growth is roughly in line with its earnings growth, suggesting a balanced valuation perspective. Notably, the company’s latest ROCE and ROE figures of 13.36% and 7.11% respectively provide some justification for the current price levels.

Despite this, the stock is trading at a discount compared to the average historical valuations of its peers, which are mostly classified as expensive or very expensive. This relative valuation improvement offers some cushion for investors but also signals that the market is pricing in tempered growth expectations going forward.

Financial Trend Remains Positive with Strong Quarterly Performance

Financially, Viyash Scientific has delivered very positive results in Q1 FY26-27, with net sales growing at an annualised rate of 20.85% and operating profit expanding by 28.24%. The company reported a remarkable 115.17% increase in net profit, continuing a streak of positive results for ten consecutive quarters. Operating profit to interest coverage reached a high of 14.26 times, underscoring improved earnings strength relative to debt servicing costs.

Profit before tax excluding other income surged by 143.51% to ₹104.10 crores, while the debt-equity ratio at half-year stood at a low 0.17 times, indicating prudent leverage management in the recent period. These metrics highlight a strong financial trend that supports the company’s operational resilience and growth prospects.

However, the average ROE of 4.59% and average ROCE of 6.09% over the longer term suggest that management efficiency and capital utilisation remain areas requiring improvement. The company’s ability to generate returns on shareholder equity is modest, which may limit upside potential despite strong top-line growth.

Technical Indicators Signal Mildly Bullish but Cautious Outlook

The technical trend for Viyash Scientific has shifted from bullish to mildly bullish, reflecting a more cautious market sentiment. Weekly MACD readings are mildly bearish, while monthly MACD remains bullish, indicating mixed momentum signals. The Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts, suggesting a neutral momentum stance.

Bollinger Bands are mildly bullish on the weekly timeframe and bullish monthly, while moving averages on the daily chart also indicate mild bullishness. However, the KST indicator is mildly bearish weekly but bullish monthly, and Dow Theory assessments are mildly bearish weekly with mildly bullish monthly readings. On-balance volume (OBV) shows no discernible trend, further underscoring the lack of strong directional conviction.

Price action remains within a range, with the current price at ₹254.65, close to the day’s high of ₹257.60 and well below the 52-week high of ₹297.90. The stock has underperformed the Sensex over the past week and month, with returns of -2.60% and -5.37% respectively, compared to Sensex declines of -1.18% and -1.17%. However, year-to-date and longer-term returns remain robust, with a 1-year return of 45.02% and a 3-year return of 190.17%, significantly outperforming the Sensex.

Balancing Strengths and Risks: What Investors Should Consider

Viyash Scientific’s recent rating downgrade to Hold reflects a nuanced view of its investment merits. The company’s strong sales and profit growth, coupled with improved quality grading and fair valuation, provide a solid foundation for long-term investors. Its consistent quarterly performance and low recent debt-equity ratio further reinforce operational stability.

Nevertheless, the modest returns on equity and capital employed, elevated leverage metrics over the medium term, and declining institutional participation raise caution flags. The mixed technical signals suggest that while the stock retains upside potential, it may face near-term volatility or consolidation.

Investors should weigh these factors carefully, considering Viyash Scientific’s position relative to sector peers and broader market conditions. The stock’s attractive year-to-date and multi-year returns highlight its capacity for wealth creation, but the Hold rating advises prudence and monitoring for clearer directional cues before committing additional capital.

Comparative Performance and Sector Context

Over the last five years, Viyash Scientific has delivered a 5.88% return compared to the Sensex’s 38.84%, indicating underperformance in the medium term. However, its 10-year return of 156.01% remains competitive against the Sensex’s 174.63%. The company’s outperformance over the past three years, with a 190.17% return versus the Sensex’s 18.92%, underscores its recent growth trajectory.

Within the Pharmaceuticals & Biotechnology sector, Viyash’s quality and valuation grades place it in the middle tier, behind leaders such as Gland Pharma and Emcure Pharma, which maintain good quality and expensive valuations. This positioning suggests that while Viyash offers value and growth, it may not yet match the operational excellence or market premium commanded by top-tier peers.

Conclusion

In summary, Viyash Scientific Ltd’s investment rating adjustment to Hold is a reflection of improved quality and valuation metrics balanced against moderate financial efficiency and mixed technical signals. The company’s strong recent financial performance and fair valuation provide a sound basis for cautious optimism, but investors should remain vigilant regarding leverage levels, institutional interest, and market momentum.

For those holding the stock, a Hold rating suggests maintaining current positions while awaiting further clarity on operational improvements and market trends. Prospective investors may find better entry points or alternative opportunities within the sector, given the evolving risk-reward profile.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →